Chemistry:Camrelizumab

From HandWiki

Camrelizumab (INN;[1] development code SHR-1210) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma.[2] PD-1 is programmed cell death protein 1.

The drug is being developed by Jiangsu HengRui Medicine Co., Ltd. As of 2019, camrelizumab is undergoing Phase II/III trials.

In China, in May 2025 camrelizumab was conditionally approved for use in combination with famitinib for the treatment of recurrent or metastatic cervical cancer in patients who have failed prior platinum-based chemotherapy and have not received prior bevacizumab.[3]

References

  1. ↑ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77". WHO Drug Information 31 (1). https://www.who.int/medicines/publications/druginformation/innlists/RL77.pdf. 
  2. ↑ "Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma". Journal of Clinical Oncology 37 (17): 1479–1489. June 2019. doi:10.1200/JCO.18.02151. PMID 31039052. 
  3. ↑ "Famitinib: First Approval". Drugs 85 (12): 1613–1620. 2025. doi:10.1007/s40265-025-02238-1. PMID 40996477. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Camrelizumab&oldid=4245391"